Merck and Pfizer’s immunotherapy ‘Bavencio’ can now be prescribed at general hospitals.

According to industry sources, the PD-L1 inhibitor Bavencio (avelumab) passed the Drug Committees (DCs) of the Big-5s general hospitals in Korea - Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, Samsung Medical Center (SMC), and Severance Hospital – as well as other major medical institutions in the nation including Inje University Seoul Paik Hospital, Ajou University Hospital, Ewha Womens University Hospital, Wonkwang University Hospital, Wonju Severance Christian Hospital, Chosun University Hospital, and Inje University Haeundae Paik Hospital.